The role of p95HER2 in trastuzumab resistance in breast cancer

ELİYATKIN N. Ö., AKTAŞ S., Ozgur H., Ercetin P., Kupelioglu A.

JOURNAL OF BUON, cilt.21, sa.2, ss.382-389, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 2
  • Basım Tarihi: 2016
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.382-389
  • Anahtar Kelimeler: breast cancer, p95HER2, trastuzumab resistance, HER2, AMPLIFICATION, MECHANISMS, EXPRESSION, EFFICACY, RECEPTOR, GROWTH, SAFETY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: Trastuzumab, the HER2 oncogene targeting drug, shows remarkable clinical efficacy in HER2-amplified breast cancer patients. Despite of robust activity, some of the patients with HER2-positive breast cancers do not get the benefit due to trastuzumab resistance. Overexpression of p95HER2 is one of the molecular mechanisms of trastuzumab resistance. The purpose of this study was to investigate whether p95HER2 overexpressing breast cancers were resistant to trastuzumab.